Madrigal Pharms

MDGL NASDAQ
99.78
-3.33
-3.23%
盘后: 99.78 0 0.00% 16:00 05/20 EDT
开盘
102.03
昨收
103.11
最高
102.88
最低
99.75
成交量
14.02万
成交均量(3M)
20.71万
52周最高
325.98
52周最低
91.56
换手率
0.91%
市值
15.38亿
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Madrigal Pharms MDGL股票价格,Madrigal Pharms股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
展开 >

最近浏览

名称
价格
涨跌幅